Provided herein are methods of using antagonists of G9a, for example, for treating cancer and/or preventing drug resistance in an individual. For example, a method of treating cancer in an individual comprising administering to the individual an antagonist of G9a alone or in combination with a cancer therapy agent is provided. In some embodiments, the antagonist of G9a increases the period of cancer sensitivity and/or delays development of cancer resistance.
